- h-index (OpenAlex)
- 80
- Papers on record · 5 on PubMed
- 5
- Stature
- Tier II
EVIDENCE RECORD
What this record is built on
Compared with the register · How it works
I · SCHOLARSHIP
- h-index
- 80 · 70th pct
- Papers on record
- 5
- Citations received
- —
II · PRACTICE
- Licence
- Not yet checked
- Board certification
- —
- Registration ID
- —
- Institutions
- 1
III · LEARNING & TEACHING
- Trainees traced
- Not yet traced
- Mentors traced
- Not yet traced
- Invited talks
- —
IV · PEER STANDING
- Honours
- —
- Techniques pioneered
- —
- Ethics mark
- Not yet audited
Not on this record by design:Star ratingsAnonymous reviewsPaid placement
Record
Özlem Türeci is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19. Türeci has served as BioNTech's chief medical officer since 2018. Since 2021, she has been Professor of Personalized Immunotherapy at the Helmholtz Institute for Translational Oncology (HI-TRON) and Johannes Gutenberg University Mainz. Türeci and her spouse, Uğur Şahin, have won a number of awards.
Institutions
- Bio
QUESTIONS YOU MIGHT ASK AT A FIRST VISIT
- Is a procedure needed now, or can medicines and lifestyle changes help first?
- What are the risks and benefits of each option for someone like me?
- How many similar cases does your team see, and who will be involved in my care?
- Who do I contact if symptoms come back after treatment?
Landmark papers
- Papers on record
- 5
- Linked to PubMed
- 5
PUBLISHED IN N Engl J Med · Nature · Science · Nat Rev Drug Discov
- 2023Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.Naturedoi 10.1038/s41586-023-06063-yPubMed ✓
- 2021A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis.Sciencedoi 10.1126/science.aay3638PubMed ✓
- 2020Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.N Engl J Meddoi 10.1056/NEJMoa2034577PubMed ✓
- 2017Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.Naturedoi 10.1038/nature23003PubMed ✓
- 2014mRNA-based therapeutics--developing a new class of drugs.Nat Rev Drug Discovdoi 10.1038/nrd4278PubMed ✓
Training and certification
- Bio
Lineage
We haven't traced this physician's mentors and trainees yet. If you trained with them, you can add to the record.Contribute lineage
FOR THE DOCTOR
Are you Özlem Türeci?
Claim this record to correct details, add your lineage and teaching, and embed your seal. Claims are checked against your registration before anything changes.